Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropinirole - Antares Pharma/Jazz Pharmaceuticals

Drug Profile

Ropinirole - Antares Pharma/Jazz Pharmaceuticals

Alternative Names: AP-1126; JZP-7; Ropinirole ATD™ Gel; Ropinirole transdermal gel

Latest Information Update: 16 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antares Pharma
  • Developer Jazz Pharmaceuticals
  • Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Restless legs syndrome

Most Recent Events

  • 10 Aug 2010 Discontinued - Phase-I for Restless legs syndrome in USA (Transdermal)
  • 15 Apr 2008 Jazz Pharmaceuticals completes a second phase I, pharmacokinetic trial for Restless legs syndrome in USA
  • 13 Mar 2008 Jazz Pharmaceuticals has completed a phase I, pharmacokinetic trial for Restless legs syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top